NCT02017912Phase 2Completed

Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS

Study sponsor: Brainstorm-Cell Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2016-03Actual
Enrollment · participants48Actual
Source updated2024-06-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview